Acumen Pharmaceuticals, Inc. (ABOS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
427 Park Street
Newton, VA 22902
United States of America (the)
Phone
434 297 1000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
July 01, 2021
| Name | Title | Pay | Year Born |
| Daniel J. O'Connell | Chief Executive Officer & Director | 972,747 | 1970 |
| Grant A. Krafft | Co-Founder | 42,000 | N/A |
| William L. Klein | Co-Founder | 42,000 | N/A |
| Caleb E. Finch | Co-Founder | 42,000 | N/A |
| Russell Barton | Chief Operating Officer | 223,680 | 1959 |
| Matt Zuga | Chief Financial Officer & Chief Business Officer | 681,780 | N/A |
| Derek Meisner | Chief Legal Officer & Corporate Secretary | 752,945 | 1971 |
| James Doherty | President & Chief Development Officer | 764,370 | 1968 |
| Alex Braun | Vice President & Head of Investor Relations | 0 | N/A |
| Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller | 0 | N/A |
| Robyn Moxon | Associate Director of Communications | 0 | N/A |
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.